期刊
LEUKEMIA & LYMPHOMA
卷 62, 期 3, 页码 598-605出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2020.1837796
关键词
PI3K inhibitor; non-Hodgkin lymphoma; idelalisib; adverse events; novel combinations
A retrospective review of 79 patients found that patients receiving novel combination therapy and previously untreated patients were more likely to develop severe adverse events. This suggests caution against the use of untested PI3K inhibitor combinations in routine practice.
Phosphoinositide-3-kinase (PI3K) inhibitors have efficacy in lymphoid malignancies; however, inflammatory and infectious toxicities can compromise the treatment course. An improved understanding of these toxicities will guide clinical use and further development. We evaluated the occurrence of treatment-related adverse events (AEs) in a retrospective review of 79 patients treated in standard fashion with PI3K inhibitor monotherapy or with anti-CD20 monoclonal antibodies or as part of a novel combination regimen. Patients treated with a novel combination were at a higher risk of developing a severe AE compared to those treated with standard therapy (HR 1.89, 95% CI 1.02, 3.49; p = .04). Additionally, previously untreated patients were at higher risk of developing a severe AE compared to previously treated patients (HR 3.19, 95% CI 1.48, 6.84; p = .003). These results caution against the use of untested PI3K inhibitor combinations in routine practice and suggest that early phase clinical trials should utilize conservative treatment schemas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据